Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea by 신재일
Clinical Trial/Experimental Study Medicine®
OPENEfﬁcacy and safety of rituximab in childhood-
onset, difﬁcult-to-treat nephrotic syndrome
A multicenter open-label trial in Korea
Yo Han Ahn, MDa, Seong Heon Kim, MDb, Kyoung Hee Han, MDc, Hyun Jin Choi, MD, PhDd,
Heeyeon Cho, MD, PhDe, Jung Won Lee, MD, PhDf, Jae Il Shin, MD, PhDg, Min Hyun Cho, MDh,
Joo Hoon Lee, MD, PhDi, Young Seo Park, MD, PhDi, Il-Soo Ha, MD, PhDd, Hae Il Cheong, MD, PhDd,
Su Young Kim, MD, PhDb, Seung Joo Lee, MD, PhDf, Hee Gyung Kang, MD, PhDd,
∗
Abstract
Background: The anti-CD20 monoclonal antibody rituximab (RTX) has been proposed as a rescue therapy for difﬁcult-to-treat
nephrotic syndrome (NS). We conducted a clinical trial to evaluate the efﬁcacy and safety of RTX in children with difﬁcult-to-treat NS
dependent on or resistant to steroids and calcineurin inhibitors (CNIs).
Methods: A multicenter open-label trial was performed at 8 major pediatric nephrology centers in Korea. The investigation
consisted of a randomized controlled trial for steroid- and CNI-dependent NS (DDNS; randomization into the RTX group and the
control group, at a ratio of 2:1) and a single-arm study of steroid and CNI-resistant NS (DRNS). DDNS patients in the RTX group and
DRNS patients received a single dose of intravenous RTX (375mg/m2 of body surface area) for B-cell depletion. A second RTX dose
was administered at week 2 if the ﬁrst dose failed to achieve depletion of CD19(+) cells. The primary endpoint was rate of maintaining
remission at 6 months after treatment for DDNS and rate of remission achievement for DRNS.
Results: Sixty-one children with DDNS were enrolled while in remission and randomized to the control group (21 patients) or the
RTX group (40 patients). At 6 months after treatment, the remission rates were 74.3% in the RTX group and 31.3% in the control
group (P= .003). The mean duration of remission maintenance was signiﬁcantly higher in the RTX group than in the control group (9.0
vs 2.9 months, P= .004). Of the 23 patients with DRNS enrolled in the single-arm study and treated with RTX, 9 (39.1%) achieved
partial or complete remission within 6 months. Depletion of B cells occurred in all patients with RTX therapy. Thirty patients (50.8% of
59 patients analyzed) experienced mild and transient infusion reaction during RTX administration, and most adverse events were
mild.
Conclusions: RTX administration was safe and effective in patients with difﬁcult-to-treat NS. One or 2 doses of RTX may be
sufﬁcient to deplete B cells and achieve better control of pediatric NS.
Abbreviations: BMI = body mass index, CNI = calcineurin inhibitor, DDNS = drug-dependent nephrotic syndrome, DRNS =
drug-resistant nephrotic syndrome, FSGS = focal segmental glomerulosclerosis, GFR = glomerular ﬁltration rate, NA = not
applicable, NS = nephrotic syndrome, RCT = randomized controlled trial, RTX = rituximab.
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In children, idiopathic nephrotic syndrome (NS) generally
responds well to corticosteroid treatment. However, most
patients become dependent on steroid treatment, with frequent
relapse. As long-term use of steroids in children is accompanied
by adverse effects such as growth impairment, obesity,
osteopenia, hypertension, and cataract, calcineurin inhibitors
(CNIs) are recommended as steroid-sparing agents.[1–4] Unfortu-
nately, CNIs remain effective only while the patient continues to
take the treatment, providing no long-lasting beneﬁts. Therefore,
many patients become dependent on CNIs, which also have side
effects such as nephrotoxicity, hypertension, and diabetes
mellitus.[3,5,6] On the contrary, 10% to 20% of NS patients
do not respond to steroid treatment; in such patients, remission is
sometimes achieved with CNI treatment, but resistance to both
steroids and CNIs is also noted. Patients who fail to achieve
remission with steroid andCNI therapy are known to have a poor
prognosis, and rapid progression to end-stage renal disease
occurs in >50% of cases.[7]
Rituximab (RTX), a monoclonal antibody targeting the CD20
antigen of B lymphocytes, has recently been introduced as rescue
therapy for difﬁcult-to-treat NS, on the basis of favorable clinical
observations.[8–13] Two randomized controlled trials (RCTs)
have proved the efﬁcacy and safety of RTX in patients with
steroid-dependent NS,[14,15] whereas another RCT reported no
beneﬁt of RTX in patients with NS-resistant to steroids and
CNIs.[16] However, some observational studies reported that
RTX induced remission in patients resistant to conventional
treatment.[17–19] The dosing regimen of RTX in NS patients
varied widely in the previous publications. In most studies, RTX
was administered at a dose of 375mg/m2 once weekly for 4
weeks, which is similar to the protocol for the treatment of B-cell
lymphoma.[10,13,15,17,18] Other studies have used single infusion
of RTX.[9,14,16] The optimal dosing schedule of RTX in NS has
not been determined.
In this study, we aimed to evaluate the efﬁcacy and safety of
single-dose RTX in childhood-onset, difﬁcult-to-treat NS
dependent on or resistant to steroids and CNIs.2. Methods
2.1. Study design
A multicenter open-label trial was conducted in Korean patients
with childhood-onset NS to evaluate the efﬁcacy and safety of
single-dose RTX. This investigation was designed as an RCT for
steroid- and CNI-dependent NS (drug-dependent NS, DDNS),
and as a single-arm study for steroid- and CNI-resistant NS
(drug-resistant NS, DRNS). Eight major centers in Korea
participated in this trial. This study was conducted in compliance
with the current version of the Declaration of Helsinki and with
the Korean Good Clinical Practice guidelines in effect at the time
of the study. The study was approved by the ethics review
committee of each participating hospital. Each participant
entered the study only after informed consent was obtained
from the legal guardians and/or the participant, as appropriate;
assent was obtained from all pediatric patients. The trial was
registered with ClinicalTrials.gov under trial registration number
NCT01716442.
The inclusion criteria were as follows: age <24 years, and
diagnosis of idiopathic NS established before the age of 18 years.
The RCT of DDNS enrolled patients with steroid dependence and
CNI dependence for >2 years, who had achieved remission with2conventional treatment consisting of oral corticosteroids (60mg/
m2/d; maximum daily dose of 60mg), with or without CNIs.
Patients not taking CNIs because of intolerance to the medication
were also considered eligible. Steroid and CNI dependence was
deﬁned as 2 consecutive relapses during steroid or CNI therapy or
within 2 weeks of discontinuation of the respective medication.
The single-arm study of DRNS enrolled patients who did not
achieve remission of NS despite continuous use of steroids and
CNIs for >3 months. The exclusion criteria were as follows:
estimated glomerular ﬁltration rate (GFR) <60mL/min/1.73m2
of body surface area; active or chronic infection; live-attenuated
vaccination within 1 month leading up to the study; underlying
cardiovascular or pulmonary disease; uncontrolled hypertension;
neutropenia or thrombocytopenia; pregnancy or potential
pregnancy; patients with known genetic causes such as NPHS1,
NPHS2, WT1, or LAMB2; and previous use of RTX.
In the RCT of DDNS, participants were randomly assigned to
the RTX group or the control group (conventional therapy) in a
ratio of 2:1, using stratiﬁed block randomization, according to
sex and age (Fig. 1A). Randomization was conducted using a
computer-generated allocation sequence on the randomization
website of Medical Research Collaborating Center of Seoul
National University Hospital. In the single-arm study of DRNS,
all patients received RTX in addition to their preenrollment
treatment with steroids and/or CNIs (Fig. 1B). All participants
were evaluated at baseline, week 2, week 4, and every 4 weeks
thereafter for 1 year. Remission and relapse of NS were deﬁned
according to the Kidney Disease: Improving Global Outcomes
(KDIGO) guideline.[1]
2.2. Treatment protocol
In the RCT of DDNS, patients in the RTX group received a single
dose of intravenous RTX (375mg/m2; maximum of 500mg) in
addition to steroids and/or CNIs, whereas patients in the control
group were treated conventionally, only with steroids and/or
CNIs. As long as remission was maintained, oral corticosteroids
were reduced to 40mg/m2 administered every other day for 4
weeks and then tapered by 25% every 4 weeks for 3 months,
followed by CNI tapering by 25% every 4 weeks. In the single-
arm study of DRNS, patients continued their preenrollment
treatment with steroids and CNIs during and after RTX
treatment (single dose of intravenous RTX; 375mg/m2; maxi-
mum of 500mg); once remission was achieved, the steroid dose
was reduced by 25% every 4 weeks, followed by CNI tapering by
25% every 4 weeks.
B-cell depletion by RTX treatment was monitored by counting
the CD19(+) cells in peripheral blood samples obtained at week 2.
This strategy was chosen because the CD19(+) cell count is
recognized as a useful B-cell marker after RTX treatment.[20] A
second RTX dose was administered if the ﬁrst dose failed to
achieve depletion of CD19(+) cells.2.3. Study outcomes and safety
The primary endpoints were the rate of maintaining remission at
6 months after enrollment for the RCT of DDNS, and the rate of
remission within 6 months after RTX administration for the
single-arm study of DRNS. The secondary endpoints of the RCT
of DDNS were the duration of remission, relapse rate per year,
duration of steroid- and CNI-free period, steroid and CNI dosage
during the study, and steroid and CNI toxicity. For the DRNS
study, the secondary endpoints were the remission rate at 3, 6, 9,
[21,22]
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Figure 1. Study design. (A) Randomized controlled trial of drug-dependent nephrotic syndrome. (B) Single-arm study of drug-resistant nephrotic syndrome.
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from enrollment to 1 year after treatment: renal function, dosage
of steroids and/or CNIs, and steroid and/or CNI toxicity. The
height Z-score, body mass index (BMI) Z-score, estimated GFR,
and prevalence of hypertension were used in the assessment of
steroid and CNI toxicity. Safety was assessed using the Common
Terminology Criteria for Adverse Events, version 4.0.2.4. Statistical analysis
In the RCT of DDNS, the required sample size was calculated
considering an expected remission rate of 60% in the RTX group
and 20% in the control group at 6 months from study entry,
according to the literature reports on RTX available at the time of
study initiation.[14] To attain 80% power at the nominal level of
2-sided alpha of 0.05, the required sample sizes were estimated as
40 participants for the RTX group and 20 participants for the
control group, considering a dropout rate of 10% in the RTX
group and 30% in the control group. To compare the 2 groups in
the RCT of DDNS, the x2 test or Fisher exact test was used for
categorical variables, whereas the 2-sample t test or Wilcoxon
rank-sum test was used for continuous values, as appropriate.
The duration of remission was analyzed using the log-rank test,
whereas time-to-event data were examined using Kaplan–Meier
analysis. The incidences of relapse and infection were calculated
as the number of events per person-years.
A similar approach was followed for estimating the required
sample size for the single-arm study of DRNS. Speciﬁcally, the
required sample size was 27 participants, considering an expected
remission rate of 40% in the study group, based on the outcomes
of standardized therapeutic studies, which reported 6-month3remission rates of <5% for steroid-resistant NS. The
remission rates were analyzed using a binomial test.
Values recorded before and after the study were compared
using the paired t test or Wilcoxon signed rank-sum test. Data
regarding hypertension and estimated GFR were analyzed using
mixed models or generalized estimating equations adjusted for
the clustering effect.3. Results
3.1. Efﬁcacy of RTX in DDNS
Sixty-one patients with DDNS were enrolled and randomly
assigned to either the RTX group (n=40) or to the control group
(n=21) (Fig. 2A). Of these, 51 participants were followed up for
>6 months and thus included in the ﬁnal analysis (RTX group,
n=35; control group, n=16). The mean age at the ﬁrst NS
diagnosed was 4.8 years. At the time of enrollment in the study,
the mean duration of treatment for NS was 8.3 years. Before
enrollment, most participants (67%) had experienced one or
more adverse effects of steroid or CNI treatment. The baseline
characteristics of the participants did not differ signiﬁcantly
between the 2 groups (Table 1).
At 6 months after enrolment, 74.3% (26/35) of patients in the
RTX groupwere at remission, whereas 68.7% (11/16) of patients
in the control group were in relapse (P= .003). The median
duration of remission throughout the study was 9.0months in the
RTX group and 2.9 months in the control group (Kaplan–Meier
analysis, P= .004; Fig. 3A). Relapse rate was signiﬁcantly lower
in the RTX group than in the control group (3.4/person-year vs
9.4/person-year, P= .006).
Allocated to RTX group  
(n=40)
Allocated to control group
 (n=21)
Randomized (n=61)
Received RTX 
(n=36)
Received conventional therapy 
(n=18)
Completed the study (n=33)
Analysed  (n=35)
Completed the study (n=16)
Analysed  (n=16)
Withdrawal after follow-up 6
 months (n=2) 
Protocol violation (n=1)
Protocol violation (n=2) 
Withdrawal by subject (n=2) 
Protocol violation (n=2) Withdrawal by subject (n=3) 
A
Enrolled (n=26)
Received RTX therapy (n=2
3)
Completed the study (n=19)
Withdrawal by subject (n=3)
Death (n=1)
Protocol violation (n=2) 
Withdrawal by subject (n=1) 
Screening (n=27)
Screening failure (n=1) 
B
Figure 2. Flowchart of patient enrollment, evaluation, and follow-up. (A) Randomized controlled trial of drug-dependent nephrotic syndrome. (B) Single-arm study
of drug-resistant nephrotic syndrome.
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lower in the RTX group than in the control group, and lower than
that noted during the year leading up to study enrollment among
patients in the RTX group; the duration of the steroid-free period
was signiﬁcantly longer in the RTX group than in the control
group (Table 2). CNIs dosage was signiﬁcantly lower, and the
duration of the CNI-free period was signiﬁcantly longer during
the study period than during the year leading up to the study
among patients in the RTX group; nevertheless, the differences
between the RTX group and the control group were not
statistically signiﬁcant (Table 2). The beneﬁcial effect of RTX in4terms of reducing the use of steroids and/or CNIs was clinically
evident as well; speciﬁcally, the height Z-scores increased and
prevalence of hypertension decreased from baseline to the end of
the study in the RTX group, whereas no such changes were noted
in the control group (Table 3). BMI and estimated GFR did not
change signiﬁcantly in either group.3.2. Efﬁcacy of RTX in DRNS
The single-arm study of DRNS enrolled 26 patients, of whom 23
were eventually treated with RTX (Fig. 2B). The mean age at the
Table 1
Baseline characteristics of patients with childhood-onset, difﬁcult-to-treat nephrotic syndrome.
Characteristic
DDNS (n=51)
DRNS (n=23)Rituximab group (n=35) Control group (n=16) P
Sex, male:female 26:9 13:3 .59 14:9
Age, y 13.5±5.0 12.5±4.2 .52 9.1±5.2
Onset of NS, years 4.8±3.3 5.1±3.0 .72 5.8±3.9
Duration of NS, years 8.7±4.9 7.4±4.9 .36 3.3±3.5
Height Z score 0.97±1.22 –1.23±1.96 .97 0.95±1.56
Body weight Z score 0.33±1.00 0.01±1.55 .45 0.06±1.84
Pathologic diagnosis
Minimal change disease 23 (65.7) 8 (50.0) .55 8 (34.8)
FSGS 2 (5.7) 1 (6.2) 10 (43.5)
C1q nephropathy 0 0 2 (8.7)
Others 0 0 2 (8.7)
Kidney biopsy not performed 10 (28.6) 7 (43.8) 1 (4.3)
Past medical history
Oral steroids 35 (100.0) 16 (100.0) NA 23 (100)
Methylprednisolone pulse 16 (45.7) 7 (43.8) .90 19 (82.6)
Cyclophosphamide 15/34 (44.1) 7/15 (46.7) .87 6 (26.1)
Cyclosporine 35 (100.0) 16 (100.0) NA 23 (100)
Tacrolimus 15/35 (42.9) 6/15 (40.0) .85 10 (43.5)
Mycophenolate mofetil 6/34 (17.6) 2/15 (13.3) >.99 7 (30.4)
Mizoribine 6/34 (17.6) 2/15 (13.3) >.99 2 (8.7)
Levamisol 7/35 (20.0) 3/15 (20.0) >.99 0
Estimated GFR, mL/min/1.73 m2 115.1±32.7 112.6±35.9 .82 124.9±63.0
Height Z score <1.88 6 (17.1) 5 (31.2) .29 7 (30.4)
Hypertension 18/35 (51.4) 5/14 (35.7) .32 10/23 (43.5)
Abnormal ophthalmologic ﬁndings 5/35 (14.3) 5/10 (50.0) .03 3/18 (16.7)
Two types of investigations were conducted, namely a randomized controlled trial of DDNS (rituximab vs control), and a single-arm study of DRNS (all patients received rituximab). Data are given as number,
number (frequency), number/total observations (frequency), or mean± standard deviation, as appropriate.
DDNS=drug-dependent nephrotic syndrome, DRNS=drug-resistant nephrotic syndrome, FSGS= focal segmental glomerulosclerosis, GFR=glomerular ﬁltration rate, NA=not applicable, NS=nephrotic
syndrome.
Ahn et al. Medicine (2018) 97:46 www.md-journal.comﬁrst diagnosis of NS was 5.8 years. At the time of enrollment, the
duration of treatment for NS was 3.3 years (Table 1). The
baseline characteristics of the participants are summarized in
Table 1. Before enrollment, 70% had experienced one or more
adverse effects of steroid or CNI treatment.Within 6months after
administration of RTX, 9 of 23 patients (39.1%) achieved partial
(n=2) or complete (n=7, 30.4%) remission of proteinuriaFigure 3. Survival analysis. (A) Kaplan–Meier analysis for relapse-free survival in
Cumulative remission rate in single-arm study of drug-resistant nephrotic syndro
5(binomial test, P< .001, Fig. 3B) The rates of partial or complete
remission at 3, 6, 9, and 12 months were 34.8%, 39.1%, 43.5%,
and 34.8%, respectively (binominal test, P< .001). The charac-
teristics of patients who achieved complete remission (n=7)
differed from those of patients who did not (n=16), especially
regarding proteinuria and serum albumin levels at the time of
RTX infusion (see Table S1, Supplemental Digital Content,the randomized controlled trial of drug-dependent nephrotic syndrome. (B)
me.
Table 2
Comparison of relapse rate, drug dose, and drug-free period in patients with childhood-onset, difﬁcult-to-treat nephrotic syndrome.
DDNS (n=51)
DRNS (n=23)Variable RTX group (n=35) Control group (n=16) P
Relapse rate/person-year 3.4±7.1 9.4±16.3 .006 NA
Drug dose, mg/kg/d
Steroids n=34a n=16 n=22b
Previous year 0.456±0.399 0.321±0.331 .19 1.131±1.870
During the study 0.235±0.192
∗∗
0.396±0.282 .02 0.426±0.620
∗
Cyclosporine n=23 n=12 n=13
Previous year 2.458±0.899 2.079±1.040 .28 4.186±2.318
During the study 1.789±1.241
∗
1.922±1.308 .77 4.348±1.968
Tacrolimus n=7 n=4 n=8
Previous year 0.095±0.049 0.084±0.018 >.99 0.098±0.058
During the study 0.068±0.067
∗
0.079±0.029 .57 0.068±0.047
Drug-free period, d/y
Steroids n=34a n=16 n=22b
Previous year 99.1±111.8 142.9±117.7 .17 123.6±151.4
During the study 140.5±91.3 80.2±98.5
∗
.02 122.0±134.8
CNIs n=30a n=16 n=21b
Previous year 31.5±55.0 49.9±93.9 .78 48.6±95.2
During the study 124.5±138.0
∗∗
78.3±144.3 .14 67.9±118.0
Two types of investigations were conducted, namely a randomized controlled trial of DDNS (RTX vs control), and a single-arm study of DRNS (all patients received RTX).
Data are given as mean± standard deviation. CNI= calcineurin inhibitor, DDNS=drug-dependent nephrotic syndrome, DRNS=drug-resistant nephrotic syndrome, NA=not applicable, RTX= rituximab.
∗
P< .05.
∗∗
P< .001 for previous year versus during the study.
aBaseline steroid and CNI dose information was not available in one patient. Because of long-term treatment with CNI, 4 patients discontinued CNI before the study.
bBaseline steroid and CNI dose information was not available in one patient. One patient was changed from cyclosporine to tacrolimus during the study period.
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the characteristics of DRNS patients stratiﬁed according to
whether complete remission was achieved within 6 months after
RTX infusion); patients with complete remission had lower
proteinuria and higher level of serum albumin (urine protein/
creatinine ratio: 2.5±2.5 vs 11.0±14.3mg/mg, P= .03; serum
albumin: 3.4±0.7 vs 2.1±0.8mg/dL, P= .002).
Steroid dosage decreased signiﬁcantly after RTX treatment,
but differences in CNI dosage and duration of drug-free period
were not evident (Table 2). Following RTX treatment, the
participants became slimmer, as BMI decreased but heightTable 3
Steroid and calcineurin inhibitor toxicity in patients with childhood-o
DD
Variable RTX group (n=35) Con
Height Z-score
At enrollment 0.97±1.22
End of the study 0.69±1.20∗∗
BMI Z-score
At enrollment 0.15±1.11
End of the study 0.16±1.05
eGFR, mL/min/1.73 m2
At enrollment 115.1±32.7
End of the study 115.7±35.0
Hypertension
At enrollment 18/35 (51.4)
End of the study 8/31 (25.8)
Two types of investigations were conducted, namely a randomized controlled trial of DDNS (RTX vs contro
number/total observations (frequency), or mean± standard deviation, as appropriate.
BMI=body mass index, CNI= calcineurin inhibitor, DDNS=drug-dependent nephrotic syndrome, DRNS
∗
P< .05.
∗∗
P< .001 for at enrollment versus end of the study.
a P value obtained using generalized estimating equation analysis.
6remained unchanged; the estimated GFR and prevalence of
hypertension did not change signiﬁcantly after RTX treatment
(Table 3).3.3. Other effects of RTX
In all patients treated with RTX, CD19(+) B cells were depleted
within 2 weeks after 1 or 2 (n=9) doses of RTX. In DDNS
patients, the proportion of B cells expressing CD19was 0.86% at
3 months and 6.08% at 6 months after treatment (Fig. 4A). The
mean duration of B-cell depletion in DDNS patients was 103.0±nset, difﬁcult-to-treat nephrotic syndrome.
NS
DRNS (n=23)trol group (n=16) P
1.23±1.96 .56 0.95±1.56
1.25±2.01 .24 0.86±1.51
0.79±1.22 .07 0.69±1.27
0.68±1.18 .13 0.26±1.37
∗
112.6±35.9 .82 124.9±63.0
110.5±19.3 .97 103.9±52.8
5/14 (35.7) .006a 10 (43.5)
7/15 (46.7) 7 (30.4)
l), and a single-arm study of DRNS (all patients received RTX). Data are given as number (frequency),
=drug-resistant nephrotic syndrome, eGFR= estimated glomerular ﬁltration rate.
Figure 4. CD19 B-cell counts after rituximab therapy. (A) Randomized controlled trial of drug-dependent nephrotic syndrome. (B) Single-arm study of drug-
resistant nephrotic syndrome.
Ahn et al. Medicine (2018) 97:46 www.md-journal.com63.7 days. Relapse after RTX treatment was not always related to
recovery of B cells; speciﬁcally, 4 patients had <1% CD19(+) B
cells at the time of NS relapse. On the contrary, the duration of B-
cell depletion after RTX treatment in DRNS patients was 40.9±
70.0 days, which is signiﬁcantly shorter than that noted among
DDNS patients (P= .004) (Fig. 4B).
3.4. Safety of RTX treatment
Regarding adverse events, 30 of 59 participants (50.8%) treated
with RTX experienced infusion reactions such as chest dis-
comfort, fever, vomiting, or skin rash, which responded to
antihistamine management and reduction in the rate of infusion.
Discontinuation of infusion was necessary in 5 patients, all of
whom were able to tolerate subsequent RTX administration.
Twenty-one patients (35.6% of RTX-treated participants)
experienced infection (mostly mild) after RTX treatment.
Overall, 45 patients (76.3% of RTX-treated participants)
experienced adverse effects; however, among DDNS patients,
there were no signiﬁcant differences between the RTX group and
the control group regarding the overall incidence of adverse
events and infection (Table 4). Reported severe adverse events
included chest discomfort, epigastric pain, periumbilical pain,
urticaria, inﬂuenza, and otitis media. One patient died of
hypertensive encephalopathy at 10 months after RTX treatment,
but the event was judged to be due to complications associated
with intractable NS, and not to RTX treatment.Table 4
Adverse events in patients with childhood-onset, difﬁcult-to-treat ne
No. of events (no. of patients) RTX group (n=36)
Total adverse events 92 (n=26)
Infusion reaction 36 (n=17)
Infection 21 (n=13)
Serious adverse event 3 (n=3)
Death 0
Two types of investigations were conducted, namely a randomized controlled trial of DDNS (RTX vs control), a
of patients).Adverse events were categorized according to the Common Terminology Criteria for Advers
DDNS=drug-dependent nephrotic syndrome, DRNS=drug-resistant nephrotic syndrome, NA=not app
74. Discussion
In this prospective clinical trial, RTXwas effective for childhood-
onset, difﬁcult-to-treat NS. A single dose of RTX treatment
increased the duration of remission, reduced the need for steroids
and CNIs (in terms of dosage and frequency of use), and induced
remission in more than one-third of DRNS patients. Adverse
events were mostly mild and transient.
In this study, the efﬁcacy of single-dose RTX in DDNS was
comparable to the efﬁcacy previously reported for treatment
involving multiple doses of RTX. Speciﬁcally, we found
remission rates of 85.7% at 3 months, whereas previous RCTs
reported 3-month remission rates of 81.5% with 1 or 2 doses of
RTX and 83.3% with 4 doses (1 per week) of RTX; at 6 months,
we found a remission rate of 74% for single-dose RTX,
compared with 75% previously reported for multiple doses of
RTX. Several other studies have also reported that single-dose or
low-dose RTX therapy is effective in nonmalignant conditions
including NS.[9,23–28] In this study, very few patients did not
achieve complete eradication of CD19(+) B cells at week 2 after
RTX infusion, and thus were given a second dose of RTX.
Complete B-lymphocyte depletion was also observed after the
ﬁrst of 4 RTX doses administered in a previous study,[15] which
reported a longer duration of B-cell depletion (B cells <1% for a
mean of 148 days, 21 weeks vs 102 days, 14.6 weeks in the
present study)[15]; however, considering that RTX treatment in
the previous study took 4 weeks (with one RTX dose per week),phrotic syndrome.
DDNS
DRNS (n=23)Control group (n=18) P
28 (n=10) .22 88 (n=19)
NA NA 24 (n=13)
4 (n=3) .72 16 (n=8)
1 (n=1) .72 16 (n=4)
0 1
nd a single-arm study of DRNS (all patients received RTX). Data are given as number of events (number
e Events, version 4.0.
licable, RTX= rituximab.
Ahn et al. Medicine (2018) 97:46 Medicinewhereas the treatment in our study consisted of a single dose of
RTX, the difference regarding duration of B-cell depletion would
actually be <3 weeks. Although the optimal dosage and interval
of RTX administration inNS are yet to be established, single-dose
RTX seems as effective as multiple-dose treatment provided that
B-cell eradication is successful.
On the contrary, the efﬁcacy of RTX for DRNS has been
questionable. Some observational studies suggested that RTX
was effective for inducing remission of NS,[17–19,29,30] and a
multicenter cohort study reported that 48.5% (16/33) of patients
with steroid-resistant NS achieved complete or partial remission
at 6 months after RTX treatment.[18] RTX in combination with
high-dose steroid and CNI treatment has been suggested as a
possible therapeutic option for patients with DRNS.[17,18]
However, an RCT reported that RTX failed to improve remission
rates over those noted for conventional therapy in DRNS.[16] In
our study, 39.1% of patients achieved partial or complete
remission within 6 months of RTX treatment, which is similar to
the ﬁndings of the previous cohort study. Such inconsistent
results might be caused by the heterogeneity of DRNS
manifestations. An international cohort study involving genetic
analysis of 27 genes known to be associated with NS found that
29.5% of steroid-resistant NS cases involved a single-gene
cause.[31] Although we excluded patients with known genetic
causes such as NPHS1, NPHS2,WT1, or LAMB2, some of our
participants might be carrying a yet unknown genetic factor of
NS. In fact, among 13 patients who did not show any response
to RTX, 3 patients were later found to harbor NUP107 gene
mutations.[32]
Compared with RTX responders, RTX nonresponders had
more severe nephrotic features at baseline. It is possible that, in
DRNS, severe proteinuria causes urinary loss of immunoglobulin
and thus of RTX, which is a monoclonal immunoglobulin G
antibody, resulting in a severely shorter half-life of RTX; indeed,
the half-life of RTX was previously reported to be <1 day.[33]
Furthermore, in our study, the duration of B-cell depletion was
much shorter in patients with DRNS than in those with DDNS. In
addition, 30.4% (7/23) of patients with DRNS compared with
only 5.7% (2/35) of patients with DDNS required a second dose
of RTX for B-cell depletion. These ﬁndings suggest that multiple-
dose RTX treatment might be more effective for inducing
remission in patients with DRNS, who would beneﬁt from
monitoring of RTX concentration and more frequent monitoring
of B-cell counts.
In patients with difﬁcult-to-treat NS, long-term use of steroids
and CNIs is associated with considerable adverse effects. Indeed,
previous studies reported steroid or CNI toxicity in 44% to 75%
of NS patients on long-term treatment,[14,15] which is consistent
with our present ﬁndings, namely, that two-thirds of patients had
experienced adverse effects of steroid or CNI treatment at the
time of enrollment in this study. RTX treatment did ameliorate
drug toxicity, especially in DDNS patients, and facilitated
signiﬁcant reduction in steroid and CNI exposure, which is in
agreement with previous observations.[15,24,34,35]
Regarding the safety of RTX, we found an infection rate of
36.1% and an in incidence of serious adverse events of 8.3% in
DDNS patients who underwent RTX treatment; these rates are
lower than those reported in a previous RCT that employed
4 doses of RTX, with one dose per week (96% and 42%,
respectively).[15] The discrepancy might stem from differences in
the use of concomitant immunosuppressive medications, or,
more likely, from the difference in cumulative dose of RTX,
which was lower in our study. Most adverse events noted in our8study, including infection, were mild and treatable. Progressive
multifocal leukoencephalopathy and pulmonary ﬁbrosis, which
represent serious adverse effects of RTX treatment,[36,37] did not
occur during the observation period of our study. However,
longer-term observation is mandatory for these patients because
such complications might develop as late adverse events.[37]
This study had some limitations. Our RCT for DDNS was not
placebo-controlled and not blinded; therefore, some bias might
be introduced. However, the authors had expected that the bias
would be minimal because our endpoints were rather objective.
On the contrary, the DRNS study had no control group. The
authors had reckoned that it was not ethical to continue
ineffective therapy in the control group during the observation
period for the purpose of the study. In addition, the observation
period of this study was one year, which was not long enough
to assess the long-term effects and safety of RTX. We need to
observe the patients enrolled in our study for a longer time to
assess the long-term outcomes.
In conclusion, our study laid one more piece of evidence that
RTX can be safe and effective in patients with childhood-onset,
medication-dependent NS. In addition, more than one-third of
patients with the medication-resistant NS may achieve remission
with RTX treatment. Finally, one dose of RTX is likely sufﬁcient
to achieve B-cell depletion in patients with NS and is moreover
associated with a lower incidence of adverse events; if necessary,
a second dose may be administered. Controlled studies are
warranted to determine the optimal dosing and interval for
administration of RTX in patients with difﬁcult-to-treat NS.Author contributions
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